Featured Research

from universities, journals, and other organizations

Penicillin Gets A "Checkmate" Against Antibiotic-Resistant Bacteria

Date:
October 9, 1998
Source:
American Chemical Society
Summary:
Groundbreaking work to alter penicillin's structure and make it effective against antibiotic-resistant strains of bacteria has been reported in the October 9, 1998 Web edition of The Journal of Organic Chemistry, published by the American Chemical Society, the world's largest scientific society. The researchers say their prototype structure offers a "checkmate stratagem" against resistant bacteria.

Groundbreaking work to alter penicillin's structure and make it effective against antibiotic-resistant strains of bacteria has been reported in the October 9, 1998 Web edition of The Journal of Organic Chemistry, published by the American Chemical Society, the world's largest scientific society. The researchers say their prototype structure offers a "checkmate stratagem" against resistant bacteria.

Penicillin's effectiveness as an antibiotic has diminished since its widespread introduction in the 1940s, due to the ability of various bacteria to develop resistance to the drug. Researchers at the University of Limerick in Ireland have taken a major first step forward by developing a "unique modification to the penicillin structure," according to Timothy Smyth, Ph.D., lead author of the report.

Some bacteria are able to negate penicillin's infection-fighting properties by producing enzymes that cleave, or cut, a critical part of the penicillin molecule. To counter this, the typical response is to combine the penicillin with a chemical substance that inhibits the action of the enzymes. After a while, the bacteria develop additional resistance to the new substance and render the updated penicillin version ineffective.

The Irish research team has produced a prototype penicillin structure that works by incorporating a unique fragment to the penicillin molecule, which is fatal to bacteria and specifically activated only when a bacterium attempts to cleave the drug's molecular structure. Any bacterium that does not produce cleaving enzymes would still be killed off by the normal action of the intact penicillin.

While Smyth acknowledges "there is some way to go yet to deliver a therapeutically useful drug," he says the work "represents the delineation and implementation of the first steps toward realizing a new approach to combat bacterial resistance to antibiotics."


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Penicillin Gets A "Checkmate" Against Antibiotic-Resistant Bacteria." ScienceDaily. ScienceDaily, 9 October 1998. <www.sciencedaily.com/releases/1998/10/981009082243.htm>.
American Chemical Society. (1998, October 9). Penicillin Gets A "Checkmate" Against Antibiotic-Resistant Bacteria. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/1998/10/981009082243.htm
American Chemical Society. "Penicillin Gets A "Checkmate" Against Antibiotic-Resistant Bacteria." ScienceDaily. www.sciencedaily.com/releases/1998/10/981009082243.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins